In August 2017, NNFE completed an angel round investment of nearly ten million Yuan of Diannei DNA. NNFE makes comprehensive arrangement of high-end medical and health industry to seize the blue ocean of trillion Yuan level market of medical health industry.
Diannei (Shanghai) DNA Co., Ltd. is a start-up company, uses big data and artificial intelligence technology, combines with the domestic scene top hospital and cooperates with the competent government departments to go into the community and to help people find and prevent early cancer through artificial intelligence in early lung cancer screening.
Diannei DNA`s relevant principal said, through the automatic identification and deep study in medical imaging, and further standard verification of the pathological report gold standard, its artificial intelligence technology can achieve early warning for lung cancer in just three minutes, with the accuracy rate of more than 80%, which has been close to the expert level.
Investment in Diannei DNA is an important step of NNFE in high-end medical health industry arrangement, opening a new model combining artificial intelligence technology and health care; at the same time, through the NNFE`s investment funds support, Diannei DNA uses financing in core technology research and development of artificial intelligence technology in medical industry, expansion of medical industry clinical applications, and construction of artificial intelligence medical teams, which provide more high-quality medical resources for users and has a positive effect on the development of high-end medical and health services, and improvement of the medical and health system.
The investment in Diannei DNA not only speeds up the industrial layout and development of the NNFE, but also cultivates a group of high-quality project enterprises, thus the multi-industry investment mode that is more mature and has new characteristics.
